MedPath

ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus

Phase 2
Active, not recruiting
Conditions
Systemic Lupus Erythematosus
Interventions
Drug: ALPN-101
Drug: Placebo
Registration Number
NCT04835441
Lead Sponsor
Alpine Immune Sciences, Inc.
Brief Summary

This is Phase 2, multinational, randomized, blinded study to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics and pharmacodynamics of ALPN-101 (acazicolcept) in adults with moderate to severe active systemic lupus erythematosus (SLE)

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
130
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ALPN-101 (acazicolcept)ALPN-101-
PlaceboPlacebo-
Primary Outcome Measures
NameTimeMethod
Adverse EventsFrom study Day 1 until End of Study (28 weeks)

Type, incidence, and severity of adverse events as assessed by CTCAE

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (46)

Investigational Site (173)

🇺🇸

Idaho Falls, Idaho, United States

Investigational Site (118)

🇺🇸

Colleyville, Texas, United States

Investigational Site (191)

🇵🇷

Caguas, Puerto Rico

Investigational Site (187)

🇵🇷

San Juan, Puerto Rico

Investigational Sites (134)

🇺🇸

Miami, Florida, United States

Investigational Site (155)

🇺🇸

Los Angeles, California, United States

Investigational Site (107)

🇺🇸

Anniston, Alabama, United States

Investigational Site (120)

🇺🇸

Hialeah, Florida, United States

Investigational Site (106)

🇺🇸

DeBary, Florida, United States

Investigational Site (152)

🇺🇸

Ormond Beach, Florida, United States

Investigational Site (133)

🇺🇸

Plantation, Florida, United States

Investigational Site (190)

🇺🇸

Tamarac, Florida, United States

Investigational Site (156)

🇺🇸

Skokie, Illinois, United States

Investigational Site (138)

🇺🇸

Grand Blanc, Michigan, United States

Investigational Site (179)

🇺🇸

Charlotte, North Carolina, United States

Investigational Site (112)

🇺🇸

Crossville, Tennessee, United States

Investigational Site (161)

🇫🇷

Paris, France

Investigational Site (186)

🇺🇸

Memphis, Tennessee, United States

Investigational Site (171)

🇺🇸

Baytown, Texas, United States

Investigational Site (143)

🇺🇸

Bellaire, Texas, United States

Investigational Site (121)

🇺🇸

Houston, Texas, United States

Investigational Site (166)

🇺🇸

Fort Worth, Texas, United States

Investigational Site (149)

🇫🇷

Marseille, France

Investigational Site (183)

🇭🇺

Székesfehérvár, Hungary

Investigational Site (128)

🇫🇷

Paris, France

Investigational Site (180)

🇭🇺

Gyula, Hungary

Investigational Site (110)

🇵🇱

Kraków, Poland

Investigational Site (108)

🇵🇱

Poznań, Poland

Investigational Site (165)

🇵🇱

Wrocław, Poland

Investigational Site (137)

🇪🇸

Coruna, Spain

Investigational Site (139)

🇪🇸

Sevilla, Spain

Investigational Site (184)

🇨🇳

Taichung, Taiwan

Investigational Site (175)

🇺🇸

Brooklyn, New York, United States

Investigational Site (169)

🇺🇸

Santa Barbara, California, United States

Investigational Site (115)

🇺🇸

Manhasset, New York, United States

Investigational Site (104)

🇺🇸

Mesquite, Texas, United States

Investigational Site (182)

🇨🇳

Taipei, Taiwan

Investigational Site (119)

🇵🇱

Poznań, Poland

Investigational Site (181)

🇭🇺

Budapest, Hungary

Investigational Site (160)

🇵🇱

ElblÄ…g, Poland

Investigational Site (189)

🇺🇸

Phoenix, Arizona, United States

Investigational Site (109)

🇺🇸

San Diego, California, United States

Investigational Site (163)

🇺🇸

Tampa, Florida, United States

Investigational Site (164)

🇺🇸

Las Vegas, Nevada, United States

Investigational Site (162)

🇺🇸

San Antonio, Texas, United States

Investigational Site (127)

🇺🇸

San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath